PIK3R1 Antibody

What is PIK3R1 and what are its primary functions in cellular signaling?

PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), including the p85α protein. These regulatory subunits associate with any of three catalytic subunits (p110α, p110β, or p110δ) to form functional PI3K heterodimers . The primary function of PIK3R1 products is to regulate the catalytic activity of PI3K, which plays a central role in signal transduction pathways involved in cell growth, proliferation, differentiation, and metabolism. In its normal state, p85α exerts an inhibitory effect on p110 catalytic subunits, helping maintain appropriate PI3K signaling levels until activation by upstream receptors .

How do PIK3R1 mutations impact PI3K signaling pathways?

PIK3R1 mutations exhibit a complex genotype-phenotype relationship with distinct clinical presentations. Heterozygous loss-of-function mutations cause SHORT syndrome, characterized by insulin resistance and short stature attributed to reduced p110α function. Conversely, heterozygous activating mutations cause immunodeficiency syndromes (APDS2) attributed to p110δ activation . Paradoxically, APDS2 patients often present with features suggesting both gain-of-function (hyperactivation of p110δ) and loss-of-function (hypofunction of p110α) effects, indicating complex interactions between mutant PIK3R1 products and different p110 catalytic subunits .

What are the most common splice site mutations in PIK3R1 and how do they affect protein function?

The most common disease-associated splice site mutations in PIK3R1 affect the splice donor site of intron 10, resulting in exon 11 skipping. Two specific variants have been identified:

• A heterozygous G-to-T mutation at position g.67589663 (the +1 position of the splice donor site)

• A heterozygous G-to-C mutation at the same nucleotide position

These mutations result in deletion of exon 11 (residues 434-475), producing a shortened p85α protein (p85α ΔEx11) that lacks part of the p110-binding domain. This alteration disrupts normal inhibitory contacts between p85α and p110 catalytic subunits, leading to hyperactivation of PI3K signaling, particularly involving p110δ in immune cells .

What epitopes should researchers target when selecting PIK3R1 antibodies for studying mutant variants?

When studying PIK3R1 mutations, especially those involving exon 11 deletion, researchers should select antibodies that target epitopes outside the deleted region to detect both wild-type and mutant proteins. For differential detection, consider using:

• Antibodies targeting the inter-SH2 domain (residues 434-475) to specifically detect wild-type p85α but not p85α ΔEx11

• Antibodies recognizing N-terminal or C-terminal epitopes to detect both wild-type and mutant proteins

• Custom antibodies directed against the novel junction created by exon 10-12 fusion in the mutant protein for specific detection of p85α ΔEx11

When studying protein interactions, selecting antibodies that don't interfere with binding domains is critical for co-immunoprecipitation experiments.

How can researchers validate the specificity of PIK3R1 antibodies for immunoassay applications?

A comprehensive validation protocol for PIK3R1 antibodies should include:

• Western blot analysis using both positive controls (cell lines known to express PIK3R1) and negative controls (PIK3R1 knockout cells)

• Immunoprecipitation followed by mass spectrometry to confirm target specificity

• Peptide competition assays using the immunizing peptide to verify epitope-specific binding

• Cross-reactivity testing against related isoforms (p55α, p50α) expressed by PIK3R1 and other regulatory subunits (p85β, p55γ) expressed by PIK3R2 and PIK3R3

• Validation in mutant cell lines or patient-derived cells to confirm detection of relevant variants

For researchers studying exon 11 deletion variants, validation should include parallel testing with wild-type cells and cells expressing p85α ΔEx11 to confirm appropriate detection patterns.

What are the optimal protocols for using PIK3R1 antibodies in co-immunoprecipitation studies of regulatory-catalytic subunit interactions?

For optimal co-immunoprecipitation of PIK3R1 with catalytic subunits, researchers should:

• Use gentle clearing by centrifugation (10,000 × g for 10 minutes) to preserve protein complexes

• Pre-clear lysates with protein A/G beads to reduce non-specific binding

• Incubate with antibodies directed against either PIK3R1 or the p110 catalytic subunit of interest (p110α or p110δ)

• Elute complexes under non-denaturing conditions when subsequent activity assays are planned

When comparing wild-type and mutant PIK3R1 interactions, parallel immunoprecipitations should be performed with equivalent protein amounts, and reciprocal IPs (pulling down with anti-p110 and probing for p85α, and vice versa) can provide confirmation of interaction differences .

How can PIK3R1 antibodies be used to assess PI3K signaling pathway activation in patient samples?

To assess PI3K pathway activation in patient samples using PIK3R1 antibodies:

• Prepare peripheral blood mononuclear cells (PBMCs) from patient and control samples

• Analyze basal and stimulation-induced (e.g., with insulin, anti-CD3/CD28) phosphorylation of downstream effectors:

  • Phospho-AKT (Ser473 and Thr308)

  • Phospho-S6 (Ser235/236)

• Compare expression levels of PIK3R1 products (p85α, p55α, p50α) and catalytic subunits

• Assess PI3K complex formation through co-immunoprecipitation experiments

• Include pathway inhibitor controls:

  • p110δ-specific inhibitor (e.g., IC87114)

  • Pan-PI3K inhibitor (e.g., Wortmannin)

  • mTOR inhibitor (e.g., rapamycin)

In patient T cell blasts with PIK3R1 splice site mutations, elevated phosphorylation of AKT is typically observed, which can be reduced by p110δ-specific inhibition, indicating that p110δ accounts for the hyperactive PI3K signaling in these cells .

How can researchers distinguish between tissue-specific effects of PIK3R1 mutations using antibody-based approaches?

To distinguish tissue-specific effects of PIK3R1 mutations, researchers should employ a multi-faceted approach:

• Compare PI3K signaling across multiple cell types from the same patient:

  • Fibroblasts (where p110α signaling predominates)

  • Lymphocytes (where p110δ signaling is prominent)

  • Adipocytes or preadipocytes (insulin-responsive tissues)

• Quantify relative expression levels of PIK3R1 products and different p110 catalytic subunits in each tissue using validated antibodies

• Assess phosphorylation of downstream effectors in response to different stimuli:

  • Insulin (activates primarily p110α-containing complexes)

  • Immune receptor engagement (activates primarily p110δ-containing complexes)

• Perform substrate-specific kinase assays after immunoprecipitation of PIK3R1:p110 complexes

In studies of APDS2 patients, PIK3R1 mutations showed cell type-specific effects: in dermal fibroblasts, no increased PI3K signaling was observed, while in immune cells, the same mutation caused hyperactivation of the pathway . This difference may be explained by varying expression levels of p110 catalytic subunits across tissues and the dominant negative effect of mutant p85α on p110α signaling .

What are the molecular mechanisms behind the paradoxical dominant negative activity of APDS2-associated PIK3R1 mutations?

The paradoxical dominant negative activity of APDS2-associated PIK3R1 mutations involves several mechanisms that can be investigated using antibody-based techniques:

• Differential binding to catalytic subunits:

  • The mutant p85α ΔEx11 fails to properly heterodimerize with p110α while still associating with p110δ

  • Co-immunoprecipitation experiments using subunit-specific antibodies can quantify these differential interactions

• Competition with wild-type regulatory subunits:

  • Mutant p85α ΔEx11 can sequester IRS1/2 without recruiting functional p110α

  • This can be assessed by immunoprecipitating IRS1/2 and probing for associated p85α (wild-type vs. mutant) and p110α

• Protein stability effects:

  • Expression levels of both mutant p85α and p110 subunits are reduced in some cell types

  • Western blotting with specific antibodies can track protein levels and stability

• Differential activation of downstream pathways:

  • Analysis of phosphorylation patterns in AKT, S6, and other effectors can reveal pathway-specific effects

This complex interplay explains why patients with APDS2 can exhibit both immunodeficiency (due to p110δ hyperactivation) and features resembling SHORT syndrome (due to dominant negative effects on p110α signaling) .

What are the optimal conditions for detecting PIK3R1 expression and phosphorylation status by immunoblotting?

For optimal detection of PIK3R1 products by immunoblotting:

• Sample preparation:

  • Use RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) with protease and phosphatase inhibitors for total protein extraction

  • For phosphorylation studies, snap-freeze samples in liquid nitrogen immediately after stimulation

• Protein separation:

  • Use 7.5-10% polyacrylamide gels for optimal separation of p85α (85 kDa) and truncated variants

  • Include positive controls (e.g., insulin-stimulated cells) and size markers

• Transfer and detection:

  • Transfer to PVDF membranes at 100V for 90 minutes for proteins >50 kDa

  • Block with 5% BSA in TBS-T for phospho-specific antibodies or 5% non-fat milk for total protein antibodies

  • Incubate with primary antibodies overnight at 4°C

• Visualization:

  • Use HRP-linked secondary antibodies and ECL detection

  • Quantify band intensities using image analysis software (e.g., Image Lab)

When comparing wild-type and mutant PIK3R1, researchers should normalize to appropriate loading controls and consider stripping and reprobing membranes to directly compare phosphorylated and total protein levels.

How can PIK3R1 antibodies be used to assess holoenzyme formation and stability in vitro?

To assess PI3K holoenzyme formation and stability using PIK3R1 antibodies:

• Co-expression system:

  • Express wild-type or mutant PIK3R1 with catalytic subunits in Sf9 insect cells

  • Purify complexes via affinity chromatography

• Quantification of complex formation:

  • Measure yields using gel filtration chromatography

  • Calculate area under the curve (280 nm mAU per mL eluted protein)

  • Normalize to the volume of infected cells

• Stability assessment:

  • Monitor complex dissociation under various conditions (temperature, pH, salt concentration)

  • Use size-exclusion chromatography coupled with immunoblotting to track subunit composition

• Functional analysis:

  • Perform lipid kinase assays using purified complexes

  • Use immunoblotting to correlate enzyme activity with complex stability

Studies have shown that PI3K holoenzyme containing p85α ΔEx11 has a low yield and reduced stability compared to wild-type complexes, which may contribute to the dominant negative effect observed in some cell types .

How can researchers distinguish between PASLI-CD and PASLI-R1 immunodeficiencies using antibody-based approaches?

Researchers can distinguish between PASLI-CD (caused by PIK3CD mutations) and PASLI-R1 (caused by PIK3R1 mutations) immunodeficiencies using these antibody-based approaches:

• Protein expression analysis:

  • PASLI-R1: Abnormal p85α size (deletion of exon 11) detectable by western blot

  • PASLI-CD: Normal p85α but potentially altered p110δ phosphorylation

• Pathway activation assessment:

  • Both conditions show hyperactivated PI3K signaling, but differential responses to specific inhibitors may be observed

  • Test response to p110δ-specific inhibitors versus pan-PI3K inhibitors

• Differential protein interaction studies:

  • Immunoprecipitate regulatory-catalytic complexes to assess:

    • PASLI-R1: Altered p85α:p110 stoichiometry, potentially reduced p110α association

    • PASLI-CD: Normal complex formation but intrinsic hyperactivation of p110δ

• Cell type-specific analyses:

  • Compare PI3K pathway activation in immune cells versus non-immune tissues

  • PASLI-R1 may show more complex tissue-specific effects due to differential expression of catalytic subunits

While both conditions present with similar clinical features (recurrent sinopulmonary infections, poor antibody responses, susceptibility to EBV and CMV, lymphoproliferation), molecular diagnosis using these approaches can guide targeted therapeutic strategies .

What experimental approaches can determine whether PI3K inhibitors may be effective for treating PIK3R1-associated immunodeficiencies?

To evaluate the potential efficacy of PI3K inhibitors for PIK3R1-associated immunodeficiencies, researchers should:

• Conduct ex vivo inhibitor studies:

  • Culture patient-derived T cell blasts or other immune cells

  • Test different inhibitors:

    • p110δ-specific inhibitors (e.g., GS1101/Idelalisib)

    • Pan-PI3K inhibitors (e.g., Wortmannin)

    • mTOR inhibitors (e.g., rapamycin)

  • Assess normalization of PI3K pathway markers:

    • AKT phosphorylation

    • S6 phosphorylation

    • Glucose uptake

    • Cell proliferation and survival

• Investigate cellular phenotype correction:

  • Measure correction of aberrant cell death (activation-induced cell death in T cells)

  • Assess restoration of B cell proliferation in response to BCR and TLR9 stimulation

  • Evaluate normalization of effector and memory T cell distributions

• Establish dose-response relationships:

  • Determine minimal effective concentrations

  • Assess potential tissue-specific responses

Studies with patient T cell blasts have demonstrated that p110δ-specific inhibition with GS1101 effectively reduces both AKT and S6 phosphorylation, suggesting that p110δ accounts for most of the hyperactive PI3K signaling in these cells. This indicates that p110δ-specific inhibitors may offer therapeutic benefit for PASLI-R1 patients, potentially with fewer side effects than broader PI3K inhibition .

How might advanced antibody engineering approaches improve detection and analysis of PIK3R1 variants?

Advanced antibody engineering approaches that could enhance PIK3R1 variant research include:

• Junction-specific monoclonal antibodies:

  • Development of antibodies specifically recognizing the novel junction created by exon 10-12 fusion in p85α ΔEx11

  • These would allow selective detection of mutant proteins without cross-reactivity with wild-type

• Conformation-sensitive antibodies:

  • Antibodies that specifically recognize the altered conformation of PIK3R1 when bound to different catalytic subunits

  • Could help detect abnormal complex formation in patient samples

• FRET-compatible antibody pairs:

  • Engineered antibody pairs enabling Förster resonance energy transfer when PIK3R1 interacts with specific partners

  • Would allow real-time monitoring of protein interactions in living cells

• Nanobodies with enhanced intracellular delivery:

  • Development of cell-permeable nanobodies targeting PIK3R1

  • Would enable intracellular tracking and potentially modulation of PIK3R1 function

These advanced approaches could significantly improve our ability to study the molecular pathogenesis of PIK3R1-associated diseases and potentially lead to novel therapeutic strategies targeting specific protein-protein interactions or conformational states .

What are the key considerations for developing PIK3R1 antibodies to study its role in diseases beyond immunodeficiency?

For studying PIK3R1's role in diseases beyond immunodeficiency, researchers should consider:

• Tissue and context specificity:

  • Develop antibodies optimized for tissues where PIK3R1 mutations cause phenotypes beyond immune dysfunction (adipose tissue, skeletal muscle, growth plate)

  • Validate in disease-relevant primary cells and tissues

• Isoform selectivity:

  • Create antibodies distinguishing between p85α, p55α, and p50α isoforms

  • Important for tissues where alternative isoform expression may compensate for mutations

• Post-translational modification detection:

  • Develop antibodies specific for phosphorylation, ubiquitination, and other modifications that regulate PIK3R1 function

  • Critical for understanding tissue-specific regulation

• Compatibility with multiplex techniques:

  • Ensure antibodies work in multi-parameter flow cytometry, mass cytometry, and multiplexed immunofluorescence

  • Enables simultaneous assessment of multiple pathway components in heterogeneous tissues

Researchers studying SHORT syndrome, insulin resistance, or growth disorders linked to PIK3R1 mutations would benefit from antibodies specifically validated in metabolic tissues and capable of detecting the subtle alterations in PI3K signaling that may be masked by compensatory mechanisms in these contexts .

What are common pitfalls in PIK3R1 immunodetection and how can researchers overcome them?

Common pitfalls in PIK3R1 immunodetection and their solutions include:

• Cross-reactivity with related isoforms:

  • Problem: Antibodies may detect p85β (PIK3R2) or p55γ (PIK3R3) due to sequence homology

  • Solution: Validate specificity using knockout cell lines; use epitopes in regions with lowest sequence homology

• Low expression level detection:

  • Problem: PIK3R1 splice variants may be expressed at low levels in certain tissues

  • Solution: Use signal amplification methods; optimize protein extraction protocols to enrich for membrane-associated fractions

• Epitope masking in protein complexes:

  • Problem: Binding partners may block antibody access to PIK3R1 epitopes

  • Solution: Test multiple antibodies targeting different regions; consider mild denaturation protocols

• Post-translational modification interference:

  • Problem: Phosphorylation or other modifications may alter antibody binding

  • Solution: Select antibodies against modification-independent epitopes; validate performance with phosphatase-treated samples

• Detection of mutant proteins:

  • Problem: Structural alterations in mutant PIK3R1 proteins may affect antibody binding

  • Solution: Use multiple antibodies targeting different epitopes; validate with recombinant mutant proteins

Research has shown that the stability of PI3K holoenzymes containing mutant PIK3R1 can be significantly reduced, which may necessitate optimization of sample preparation protocols to prevent protein degradation during experimental processing .

How can researchers quantitatively assess PIK3R1-dependent signaling in complex tissue samples?

For quantitative assessment of PIK3R1-dependent signaling in complex tissue samples:

• Single-cell analysis approaches:

  • Phospho-flow cytometry to measure PI3K pathway activation at the single-cell level

  • Mass cytometry (CyTOF) for simultaneous detection of multiple phospho-proteins

  • Enables identification of cell-specific responses within heterogeneous tissues

• Spatial analysis techniques:

  • Multiplexed immunofluorescence to assess pathway activation in intact tissue architecture

  • Proximity ligation assays to detect specific protein-protein interactions in situ

  • Important for understanding tissue microenvironment effects on PIK3R1 function

• Quantitative mass spectrometry:

  • Phosphoproteomics to globally assess pathway activation

  • Immunoprecipitation-mass spectrometry to identify PIK3R1 interaction partners

  • Provides comprehensive view of signaling network alterations

• Normalization strategies:

  • Use of multiple housekeeping proteins for accurate normalization

  • Inclusion of phosphatase inhibitors to preserve phosphorylation status

  • Standardized positive controls (e.g., insulin stimulation) for inter-assay comparability

These approaches are particularly valuable for studying PIK3R1 mutations in patient tissues, where cell type-specific effects and compensatory mechanisms may complicate the interpretation of bulk analyses .